Adult-onset Still's disease classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents into systemic sub-type and chronic arthritis sub-type. The sub-types differ based on the cytokine profile, clinical course and response to treatment.
Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents into [[systemic]] sub-type and chronic [[arthritis]] sub-type. The sub-types differ based on the [[cytokine]] profile, clinical course and response to treatment.


==Classification==
==Classification==
Line 10: Line 10:
=== Classification based on clinical presentation ===
=== Classification based on clinical presentation ===
Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents. The following are the sub-types:<ref name="pmid15642140">{{cite journal |vauthors=Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA |title=Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome |journal=Arthritis Res. Ther. |volume=7 |issue=1 |pages=R30–7 |date=2005 |pmid=15642140 |pmc=1064882 |doi=10.1186/ar1453 |url=}}</ref><ref name="pmid22605480">{{cite journal |vauthors=Lee SJ, Cho YN, Kim TJ, Park SC, Park DJ, Jin HM, Lee SS, Kee SJ, Kim N, Yoo DH, Park YW |title=Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells |journal=Arthritis Rheum. |volume=64 |issue=9 |pages=2868–77 |date=September 2012 |pmid=22605480 |doi=10.1002/art.34514 |url=}}</ref>
Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents. The following are the sub-types:<ref name="pmid15642140">{{cite journal |vauthors=Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA |title=Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome |journal=Arthritis Res. Ther. |volume=7 |issue=1 |pages=R30–7 |date=2005 |pmid=15642140 |pmc=1064882 |doi=10.1186/ar1453 |url=}}</ref><ref name="pmid22605480">{{cite journal |vauthors=Lee SJ, Cho YN, Kim TJ, Park SC, Park DJ, Jin HM, Lee SS, Kee SJ, Kim N, Yoo DH, Park YW |title=Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells |journal=Arthritis Rheum. |volume=64 |issue=9 |pages=2868–77 |date=September 2012 |pmid=22605480 |doi=10.1002/art.34514 |url=}}</ref>
* ASOD with pre-dominant systemic symptoms
* ASOD with pre-dominant [[systemic]] [[symptoms]]
* ASOD with pre-dominant arthritis
* ASOD with pre-dominant [[arthritis]]
{| class="wikitable"
{| class="wikitable"
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Adult-onset Still's disease sub-types
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Adult-onset Still's disease sub-types
Line 25: Line 25:
|-
|-
|
|
* Natural killer (NK) cell dysfunction (marked deficiency)
* [[Natural killer cell|Natural killer (NK) cell]] dysfunction (marked deficiency)
* CD8 type (cytotoxic) T cell dysfunction (marked deficiency)
* [[Cytotoxic T cell|CD8 type (cytotoxic) T cell]] dysfunction (marked deficiency)
* Neutrophil, monocyte and macrophage activation
* [[Neutrophil]], [[monocyte]] and [[macrophage]] activation
|
|
* Interleukin 1 beta
* [[Interleukin 1 beta]]
* Interleukin 18
* [[Interleukin 18]]
* Interferon alpha and beta
* [[Interferon alpha]] and beta
* Interleukin 4
* [[Interleukin 4]]
|
|
* Arhtraligia
* [[Arthralgia]]
* Myalgia
* [[Myalgia]]
* Hepatitis
* [[Hepatitis]]
* Spleenomegaly
* [[Spleenomegaly]]
* Spiking fever (evening spike)
* Spiking [[fever]] (evening spike)
* Orbital inflammation
* [[Orbit (anatomy)|Orbital]] [[inflammation]]
* Cardiac dysfunction
* [[Cardiac]] dysfunction
* Pulmonary dysfucntion
* [[Pulmonary]] dysfucntion
* Weight loss
* [[Weight loss]]
* Sore throat
* [[Sore throat]]
* Lymphadenopathy
* [[Lymphadenopathy]]
|
|
* Thrombocytopenia
* [[Thrombocytopenia]]
* Hyperferritinemia
* Hyperferritinemia
|
|
* Strong response to interleukin-1 inhibitors
* Strong response to [[Interleukin 1|interleukin-1]] inhibitors
* Weak response to interleukin 18 inhibitors and interferon gamma inhibitors
* Weak response to [[interleukin 18]] inhibitors and [[interferon gamma]] inhibitors
|
|
* Upregulation of genes involved in granulocyte formation
* Upregulation of [[genes]] involved in [[granulocyte]] formation
|-
|-
!Arthritis sub-type
!Arthritis sub-type
|
|
* Natural killer (NK) cell dysfunction (deficiency)
* [[Natural killer cells|Natural killer (NK) cell]] dysfunction (deficiency)
* CD8 type (cytotoxic) T cell dysfunction (deficiency)
* [[Cytotoxic T cell|CD8 type (cytotoxic) T cell]] dysfunction (deficiency)
* Neutrophil, monocyte and macrophage activation
* [[Neutrophil]], [[monocyte]] and [[macrophage]] activation
|
|
* Interleukin 17
* [[Interleukin 17]]
* Interleukin 23
* [[Interleukin 23]]
* Interleukin 6
* [[Interleukin 6]]
* Tumor necrosis factor alpha (TNF-alpha)
* [[Tumor necrosis factor alpha|Tumor necrosis factor alpha (TNF-alpha)]]
|
|
* Involvement of wrist, ankle, elbow joints, proximal interphalyngeal joints (PIP)
* Involvement of [[wrist]], [[ankle]], [[Elbow-joint|elbow]] joints, [[Proximal interphalangeal joints|proximal interphalyngeal joints]] (PIP)
* Arthralgia
* [[Arthralgia]]
* Myalgia
* [[Myalgia]]
* Spiking fever
* Spiking [[fever]]
* Salmon-colored maculopapular rash
* Salmon-colored [[maculopapular]] rash
* Less common systemic and organ involvement
* Less common [[systemic]] and organ involvement
|
|
* Thrombocytosis
* [[Thrombocytosis]]
* Arthritis
* [[Arthritis]]
|
|
* Strong response to interleukin 6 inhibitors
* Strong response to [[interleukin 6]] inhibitors
* Good response to TNF-alpha inhibitors
* Good response to [[Tumor necrosis factor-alpha|TNF-alpha]] inhibitors
* Weak reponse to interleukin 17 inhibitors
* Weak reponse to [[interleukin 17]] inhibitors
|
|
|}
|}

Latest revision as of 04:50, 23 April 2018

Adult-onset Still's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adult-onset Still’s Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Adult-onset Still's disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Template:Adult-onset Still's disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adult-onset Still's disease classification

CDC on Template:Adult-onset Still's disease

Template:Adult-onset Still's disease in the news

Blogs on Template:Adult-onset Still's disease

Risk calculators and risk factors for Template:Adult-onset Still's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents into systemic sub-type and chronic arthritis sub-type. The sub-types differ based on the cytokine profile, clinical course and response to treatment.

Classification

Classification based on clinical presentation

Adult-onset Stiil's disease (AOSD) may be classified based on the predominant clinical picture with which the patient presents. The following are the sub-types:[1][2]

Adult-onset Still's disease sub-types Systemic sub-type Distinguishing features
Pre-dominant cellular mechanism Cytokine profile Clinical presentation Laboratory findings Response to treatment Miscellaneous
Arthritis sub-type

References

  1. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA (2005). "Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome". Arthritis Res. Ther. 7 (1): R30–7. doi:10.1186/ar1453. PMC 1064882. PMID 15642140.
  2. Lee SJ, Cho YN, Kim TJ, Park SC, Park DJ, Jin HM, Lee SS, Kee SJ, Kim N, Yoo DH, Park YW (September 2012). "Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells". Arthritis Rheum. 64 (9): 2868–77. doi:10.1002/art.34514. PMID 22605480.